Hadassah Medical Center

Vintage Investment Partners Announces Two New Members of Its Strategic Advisory Board

Retrieved on: 
Tuesday, January 30, 2024
Entrepreneurship, Senior, Presidency of Barack Obama, GBS, National Council, Former, Hadassah Medical Center, Research, Ovarian cancer, Hebrew University of Jerusalem, Bank, Genius, CFA, Bank of Israel, University, LLB, Fidelity, Central Waqf Council, Economics, PGD, P&G, Education, Strauss Group, MIT, Berkshire Partners, Analysis Group, SAB, Bank Leumi, GMO, CDPQ, Finance, Harvard University, Doctor of Philosophy, First Nations in Manitoba, Cincinnati metropolitan area, Defense, IBM Consulting, Bed Bath & Beyond, Teaching, Management

Dr. Haj-Yehia served between 2019-2023 as Executive Group Chairman of Bank Leumi, the largest and oldest bank in Israel.

Key Points: 
  • Dr. Haj-Yehia served between 2019-2023 as Executive Group Chairman of Bank Leumi, the largest and oldest bank in Israel.
  • "I am thrilled to have Samer and Andy join our Strategic Advisory Board.
  • More importantly, both bring unique experience and perspectives to Vintage that we are thrilled to tap", said Alan Feld, Founder and Co-Managing Partner of Vintage.
  • The other members of the Vintage SAB include: Bradley Bloom, Former Chairman and Co-Founder of Berkshire Partners, Mark Dubowitz, CEO, Foundation for the Defense of Democracies, Ambassador S. Fitzgerald Haney, Former U.S.

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 16, 2023
Alpha Sigma Tau, Carcinoma, Pancreatic cancer, Neck, Liver disease, Safety, Financial result, Food, Toxicity, Hadassah Medical Center, Clinical trial, Government, Radiation, Patient, FDA, PMDA, Marketing, G&A, Restart, Lung cancer, Lawrence, Massachusetts, Trial of the century, Manager, Financial toxicity, Alpha, Coronavirus Scientific Advisory Board, Itch, Brain, Pharmaceutical industry, Medical imaging

JERUSALEM, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update.

Key Points: 
  • - Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underway in Montreal, Canada -
    JERUSALEM, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update.
  • Planning treatment of the first patient in the Canadian liver metastases safety and feasibility trial in Q4 2023 or Q1 2024.
  • As of September 30, 2023, the Company had cash, restricted cash, deposits and restricted deposits in the amount of $90.1 million, compared to $105.4 million on December 31, 2022.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.

Southern Glazer’s Wine & Spirits Supports Humanitarian Relief in Israel

Retrieved on: 
Wednesday, October 11, 2023
Professional Services, DEI (Diversity, Equity and Inclusion), Retail, Restaurant, Bar, Wine & Spirits, Food, Beverage, Hadassah Medical Center, Organization, Hamas, Violence, Hope, Southern Glazer's Wine and Spirits, Hatred

Southern Glazer's Wine & Spirits (Southern Glazer's)—the world’s preeminent distributor of beverage alcohol—supports the people of Israel.

Key Points: 
  • Southern Glazer's Wine & Spirits (Southern Glazer's)—the world’s preeminent distributor of beverage alcohol—supports the people of Israel.
  • Following the recent attack by Hamas terrorists, the Company reiterates its stance against hate, discrimination, and violence in any form.
  • These organizations are on the ground providing emergency medical and humanitarian services to the thousands injured and in crisis.
  • As the world watches the aftermath of this horrifying terrorist attack, Southern Glazer’s expresses its support for Israel.

Nexcella Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
Travel, Hematopoietic stem cell transplantation, AUC, AL amyloidosis, MRD, Hadassah Medical Center, AL, Patient, IMS, Amyloidosis, LOS, Daratumumab, BCMA, Pharmaceutical industry, Immunotherapy

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced presentation of additional AL Amyloidosis clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, at an oral presentation at the 20th International Myeloma Society Annual (IMS) Meeting being held in Athens, Greece on September 27-30 2023. One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update. All patients were DARZALEX® (daratumumab) combination therapy relapsed/refractory and experienced a median of 6 earlier treatments that failed to stop worsening of disease (lines of therapy) prior to receiving NXC-201.

Key Points: 
  • One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update.
  • “NXC-201’s 100% response rate in relapsed/refractory AL amyloidosis patients, including t(11;14) and cardiac involved, indicates a potential broad mechanism of action.
  • Median follow-up was 7.3 months (range: 2.5 – 16.5 months) as of the September 20, 2023 data cutoff.
  • Data highlights:
    Best responder had a duration of response of 19.2 months as of the data cutoff of September 20, 2023, with response ongoing
    For the 7 relapsed/refractory AL Amyloidosis patients with cardiac involvement:
    4 patients with t(11;14) relapsed/refractory AL Amyloidosis:
    The 20th IMS AL Amyloidosis presentation can be accessed on the Nexcella corporate website at this link: https://nexcella.com/publications/
    20th International Myeloma Society Annual Meeting, Athens, Greece

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
Travel, Hematopoietic stem cell transplantation, AUC, AL amyloidosis, Thirty Days, MRD, Hadassah Medical Center, AL, Patient, IMS, Amyloidosis, LOS, Daratumumab, BCMA, Pharmaceutical industry, Hospital, Immunotherapy

One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update.

Key Points: 
  • One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update.
  • “NXC-201’s 100% response rate in relapsed/refractory AL amyloidosis patients, including t(11;14) and cardiac involved, indicates a potential broad mechanism of action.
  • Median follow-up was 7.3 months (range: 2.5 – 16.5 months) as of the September 20, 2023 data cutoff.
  • Data highlights:
    Best responder had a duration of response of 19.2 months as of the data cutoff of September 20, 2023, with response ongoing
    For the 7 relapsed/refractory AL Amyloidosis patients with cardiac involvement:
    4 patients with t(11;14) relapsed/refractory AL Amyloidosis:
    The 20th IMS AL Amyloidosis presentation can be accessed on the ImmixBio corporate website at this link: https://immixbio.com/pipeline/#publications
    20th International Myeloma Society Annual Meeting, Athens, Greece

P-Cure Collaborates with RaySearch on P-Cure's Gantry-Less Seated Proton System Designed to Fit within Linac Vaults

Retrieved on: 
Monday, October 2, 2023
Proton, Partnership, Proton therapy, RaySearch Laboratories, Head, Neck, CNS, Hadassah Medical Center, FDA, Environment, Automation, Medical imaging, Pharmaceutical industry

The partnership is an organic continuation of the existing relationship between the companies that already resulted in integration of RayStation, the RaySearch treatment planning system, in a study conducted at the P-Cure Clinical Development Center operated clinically by Hadassah -- the only available proton facility in the Middle East.

Key Points: 
  • The new P-Cure and RaySearch collaboration will enable users of the P-Cure Proton Therapy System to use RayStation and RayCare in a seamlessly integrated environment.
  • SHILAT, Israel, Oct. 2, 2023 /PRNewswire-PRWeb/ -- The new P-Cure and RaySearch collaboration will enable users of the P-Cure Proton Therapy System to use RayStation and RayCare in a seamlessly integrated environment.
  • The P-Cure Proton Therapy System is a compact gantry-less proton therapy solution that has been recently cleared by the FDA.
  • P-Cure is a pioneer in the development of upright radiation therapy and the ability to provide a proton system in a regular Linac room has great potential to expand proton therapy."

Nexcella Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Retrieved on: 
Monday, October 2, 2023
Hematopoietic stem cell transplantation, Hospital, Multiple myeloma, AL amyloidosis, Cell, Clinical data repository, Hadassah Medical Center, Patient, Data, IMS, Amyloidosis, LOS, IND, BCMA, Safety, Pharmaceutical industry, Medical device, Immunotherapy

95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy.

Key Points: 
  • 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy.
  • “We feel these overall response rate data are compelling as 72% was the overall response rate reported for ABECMA from its pivotal 100-patient KarMMa trial in relapsed/refractory multiple myeloma.
  • “The waiting lists at major academic medical centers in the United States for multiple myeloma CAR-Ts reflect unmet medical need.
  • This could meaningfully reduce hospital costs and enable NXC-201 CAR-T therapy to be widely adopted.”
    The 20th IMS multiple myeloma poster can be accessed on the Nexcella corporate website at this link: https://nexcella.com/publications/
    Nexcella Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
    20th International Myeloma Society Annual Meeting, Athens, Greece

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Retrieved on: 
Monday, October 2, 2023
Hematopoietic stem cell transplantation, Hospital, Multiple myeloma, AL amyloidosis, Cell, Clinical data repository, Hadassah Medical Center, Patient, Data, IMS, Amyloidosis, LOS, IND, BCMA, Safety, Pharmaceutical industry, Medical device, Immunotherapy

LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. The updated dataset consists of 63 multiple myeloma patients (including data on 13 new patients and continued follow-up data on 50 previously enrolled patients), at a poster presentation at the 20th International Myeloma Society Annual Meeting in Athens, Greece on September 27-30, 2023 (72 patient count includes 9 AL Amyloidosis patients which will be announced separately).

Key Points: 
  • 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy.
  • “We feel these overall response rate data are compelling as 72% was the overall response rate reported for ABECMA from its pivotal 100-patient KarMMa trial in relapsed/refractory multiple myeloma.
  • “The waiting lists at major academic medical centers in the United States for multiple myeloma CAR-Ts reflect unmet medical need.
  • This could meaningfully reduce hospital costs and enable NXC-201 CAR-T therapy to be widely adopted.”
    The 20th IMS multiple myeloma poster can be accessed on the ImmixBio corporate website at this link: https://immixbio.com/pipeline/#publications
    Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
    20th International Myeloma Society Annual Meeting, Athens, Greece

RaySearch deepens collaboration with P-Cure

Retrieved on: 
Monday, October 2, 2023
Neck, RaySearch Laboratories, Hadassah Medical Center, Partnership, FDA, Head, Environment, Automation, Proton therapy, CNS, Pharmaceutical industry, Medical imaging

STOCKHOLM, Oct. 1, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce its expanded collaboration with P-Cure, aiming at enhancing the workflow efficiency of P-Cure's proton therapy system through integration with RaySearch's systems RayStation®* and RayCare®*.

Key Points: 
  • STOCKHOLM, Oct. 1, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce its expanded collaboration with P-Cure, aiming at enhancing the workflow efficiency of P-Cure's proton therapy system through integration with RaySearch's systems RayStation®* and RayCare®*.
  • The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment.
  • The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA.
  • Johan Löf, founder and CEO, RaySearch, says: "We are proud to work with a company that is ushering in a new era of proton therapy.

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center

Retrieved on: 
Thursday, September 14, 2023
Pancreatic cancer, Alpha Sigma Tau, Alpha, Survival, Clinical trial, Cancer, Hope, Patient, Hadassah Medical Center, Safety, Pharmaceutical industry

JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that a patient with advanced inoperable pancreatic cancer has been treated in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.

Key Points: 
  • JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that a patient with advanced inoperable pancreatic cancer has been treated in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.
  • “We are dedicated to improving the lives and giving hope to cancer patients and their families, and we believe that Alpha DaRT has the potential to transform the treatment landscape for malignant tumors worldwide,” said Alpha Tau CEO Uzi Sofer.
  • “The procedure was smooth, straightforward, and incredibly quick, thanks to the support of the Alpha Tau team.
  • The Alpha DaRT treatment holds promise and gives hope for pancreatic cancer patients and their families.”
    “Pancreatic cancer is particularly devastating, with an estimated 5-year survival rate of less than 5%,” commented Alpha Tau CMO Dr. Robert Den.